Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

2025-12-03 14:16:44 ET

I'm initiating coverage of Trevi Therapeutics ( TRVI ) with a "Buy" rating, and the reason why is because it is already ahead of the game in terms of getting its lead program into phase 3 testing. I'm talking about the development of Haduvio [oral nalbuphine ER] for the treatment of cough in patients with idiopathic pulmonary fibrosis [IPF]. Consider that the company has already been able to achieve positive topline results from the phase 2b CORAL study and is expected to file a meeting request with the FDA in Q4 of 2025. This is a crucial inflection point because if talks go well, then the company should be able to initiate a phase 3 study using Haduvio for the treatment of IPF patients with chronic cough in the 1st half of 2026. Bottom line is that this program is important because it is an unmet need, as there is currently no FDA-approved therapy for a majority of these IPF patients with chronic cough....

Read the full article on Seeking Alpha

For further details see: